OA13308A - Use of polypeptides of cupredoxin family in cancertherapy. - Google Patents

Use of polypeptides of cupredoxin family in cancertherapy. Download PDF

Info

Publication number
OA13308A
OA13308A OA1200600056A OA1200600056A OA13308A OA 13308 A OA13308 A OA 13308A OA 1200600056 A OA1200600056 A OA 1200600056A OA 1200600056 A OA1200600056 A OA 1200600056A OA 13308 A OA13308 A OA 13308A
Authority
OA
OAPI
Prior art keywords
lys
gly
thr
val
asp
Prior art date
Application number
OA1200600056A
Other languages
English (en)
Inventor
Ananda M Chakrabarty
Gupta Tapas K Das
Yoshinori Hiraoka
Vasu Punj
Tohru Yamada
Olga Zaborina
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of OA13308A publication Critical patent/OA13308A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/415—Cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
OA1200600056A 2003-08-15 2004-08-10 Use of polypeptides of cupredoxin family in cancertherapy. OA13308A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41455003P 2003-08-15 2003-08-15
US10/720,603 US7491394B2 (en) 2001-02-15 2003-11-24 Cytotoxic factors for modulating cell death

Publications (1)

Publication Number Publication Date
OA13308A true OA13308A (en) 2007-04-13

Family

ID=34221130

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200600056A OA13308A (en) 2003-08-15 2004-08-10 Use of polypeptides of cupredoxin family in cancertherapy.

Country Status (19)

Country Link
US (4) US7491394B2 (fr)
EP (2) EP1653990B1 (fr)
JP (1) JP2007502818A (fr)
KR (1) KR20060098358A (fr)
AP (1) AP2006003537A0 (fr)
AT (1) ATE470672T1 (fr)
AU (1) AU2004266632A1 (fr)
BR (1) BRPI0413574A (fr)
CA (1) CA2535581A1 (fr)
DE (1) DE602004027637D1 (fr)
EA (1) EA009897B1 (fr)
EC (1) ECSP066422A (fr)
GE (1) GEP20105022B (fr)
IL (1) IL173576A0 (fr)
NO (1) NO20061168L (fr)
NZ (1) NZ545355A (fr)
OA (1) OA13308A (fr)
TN (1) TNSN06059A1 (fr)
WO (1) WO2005018662A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) * 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7618939B2 (en) 2001-02-15 2009-11-17 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US7338766B2 (en) * 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
US9434770B2 (en) * 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
KR20080019615A (ko) * 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
BRPI0612424A2 (pt) * 2005-05-20 2009-01-27 Univ Illinois composiÇÕes e mÉtodos para tratar condiÇÕes relacionadas com a sinalizaÇço da efrina com cupredoxinas
WO2006127514A2 (fr) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions et methodes pour traiter une infection vih a l'aide de cupredoxine et de cytochrome c
WO2007024368A2 (fr) * 2005-07-19 2007-03-01 The Board Of Trustees Of The University Of Illinois Compositions et methodes de controle de angiogenese a l'aide de cupredoxines
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
US10266868B2 (en) 2006-05-19 2019-04-23 The Board Of Trustees Of The University Of Illinois Compositions for treating HIV infection with cupredoxin and cytochrome C
SG174108A1 (en) * 2006-09-11 2011-09-29 Univ Illinois Modifications of cupredoxin derived peptides and methods of use thereof
MX2009002787A (es) * 2006-09-14 2009-08-27 Univ Illinois Composiciones y métodos para prevenir el cáncer con cupredoxinas.
BRPI0718360A2 (pt) * 2006-12-04 2013-11-12 Univ Illinois "composições e métodos para o tratamento do câncer com cupredoxinas e dna rico em cpg"
WO2008086523A2 (fr) * 2007-01-11 2008-07-17 The Board Of Trustees Of The University Of Illinois Compositions et méthodes permettant de traiter des affections associées à la signalisation de l'éphrine avec des cuprexodines et des mutants de celles-ci
JP2010518123A (ja) 2007-02-08 2010-05-27 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 癌をキュプレドキシンで予防するための組成物および方法
PE20110367A1 (es) * 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
EP2971039B1 (fr) 2013-03-14 2020-01-01 Immusoft Corporation Procédé de différentiation et de transduction in vitro de lymphocytes b à mémoire avec des vecteurs viraux pseudotypés vsv-g
EP4177336A1 (fr) 2014-12-19 2023-05-10 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques
US11136613B2 (en) 2015-04-30 2021-10-05 Board Of Regents, The University Of Texas System Antibacterial polypeptide libraries and methods for screening the same
CN111705026B (zh) * 2020-06-02 2021-11-26 华中农业大学 一种牛支原体Mbov_0280基因突变株及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4585644A (en) 1984-06-04 1986-04-29 Phillips Petroleum Company Changing oil tubes in a carbon black reactor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
ATE165516T1 (de) 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5789389A (en) 1995-03-17 1998-08-04 Board Of Trustees Of University Of Illinois BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
EP1411963A4 (fr) 2001-02-15 2005-01-19 Univ Illinois Facteurs cytotoxiques destines a moduler la mort cellulaire
US7301010B2 (en) 2001-02-15 2007-11-27 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating HIV infection with cupredoxin and cytochrome c
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
CN1863545A (zh) 2003-08-15 2006-11-15 伊利诺斯大学理事会 Cupredoxin家族多肽在癌症治疗中的用途
EA200700813A1 (ru) 2004-10-07 2008-10-30 Ананда Чакрабарти Транспортирующие вещества, производные купредоксина и способы их применения
WO2006127514A2 (fr) 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions et methodes pour traiter une infection vih a l'aide de cupredoxine et de cytochrome c
KR20080019615A (ko) 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法

Also Published As

Publication number Publication date
AU2004266632A1 (en) 2005-03-03
JP2007502818A (ja) 2007-02-15
US20140179617A1 (en) 2014-06-26
BRPI0413574A (pt) 2006-10-17
CA2535581A1 (fr) 2005-03-03
US20060292136A1 (en) 2006-12-28
US10421801B2 (en) 2019-09-24
GEP20105022B (en) 2010-06-25
AP2006003537A0 (en) 2006-04-30
TNSN06059A1 (en) 2007-10-03
EP1653990B1 (fr) 2010-06-09
US7491394B2 (en) 2009-02-17
DE602004027637D1 (de) 2010-07-22
EA200600424A1 (ru) 2006-08-25
NZ545355A (en) 2009-10-30
IL173576A0 (en) 2006-07-05
EA009897B1 (ru) 2008-04-28
WO2005018662A1 (fr) 2005-03-03
KR20060098358A (ko) 2006-09-18
NO20061168L (no) 2006-05-15
US20060040269A1 (en) 2006-02-23
US20080182782A1 (en) 2008-07-31
EP1653990A1 (fr) 2006-05-10
ECSP066422A (es) 2006-11-24
ATE470672T1 (de) 2010-06-15
EP2263682A1 (fr) 2010-12-22
US7888468B2 (en) 2011-02-15

Similar Documents

Publication Publication Date Title
US10421801B2 (en) Cytotoxic factors for modulating cell death
US10266573B2 (en) Cytotoxic factors for modulating cell death
US7740857B2 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
AU2002311753A1 (en) Cytotoxic factors for modulating cell death
US8124055B2 (en) Compositions and methods to control angiogenesis with cupredoxins
ZA200602126B (en) Use of polypeptides of the cupredoxin family in cancer therapy
AU2010201360A1 (en) Compositions and methods for treating malaria with cupredoxin and cytochrome
KR20080024124A (ko) 쿠프레독신과 시토크롬 ｃ로 ｈｉｖ 감염을 치료하기 위한조성물과 방법
EP1904081A2 (fr) Compositions et methodes de controle de angiogenese a l'aide de cupredoxines
MXPA06001820A (en) Use of polypeptides of the cupredoxin family in cancer therapy